NasdaqGS:CTKBLife Sciences
Cytek Biosciences (CTKB) Margin Worsening With Q4 Loss Challenges Bullish Narratives
Cytek Biosciences (CTKB) closed out FY 2025 with Q4 revenue of US$62.1 million and a basic EPS loss of US$0.34, alongside a trailing twelve month revenue base of US$201.5 million and a basic EPS loss of US$0.52. Over recent periods, the company has seen quarterly revenue move from US$57.5 million in Q4 2024 to US$62.1 million in Q4 2025, while basic EPS shifted from a profit of US$0.07 in Q4 2024 to a loss of US$0.34 in Q4 2025. This sets up a story that puts margin pressure and the path back...